[EN] ANTI-GM1 ANTIBODY BINDING COMPOUNDS<br/>[FR] COMPOSÉS DE LIAISON À UN ANTICORPS ANTI-GM1
申请人:[en]POLYNEURON PHARMACEUTICALS AG
公开号:WO2022224035A2
公开(公告)日:2022-10-27
This disclosure provides glycan-conjugated compounds that specifically bind to anti -GM1 autoantibodies. These glycan-conjugated compounds can include a polymer backbone or support configured to display multiple glycan groups that are designed to mimic the natural GM1 epitope. The glycan-conjugated compounds can also be configured on a solid support. The linked glycan groups can be a novel analogue of the GM1 epitope. When several such glycan groups are configured on a polymeric backbone, the resulting compound provides for potent and specific binding to anti-GM1 IgG and IgM isotype autoantibodies in patient sera. This disclosure thus provides glycan-containing compounds of formula (I) that mimic the natural GM1 epitope, and therapeutically useful polymers that include a multitude of such ligands, designed to bind anti-GM1 antibodiesin vitrofor diagnostic use, and to sequester and eliminate anti-GM1 antibodiesin vivoor extracorporeal (ex vivo) for the treatment anti-GM1 autoantibody related neuropathies.